表紙
市場調査レポート

中枢神経系疾患の治験におけるエンドポイント:広く採用されている複数のエンドポイントと評価スケール

Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted

発行 GBI Research 商品コード 224309
出版日 ページ情報 英文 216 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
中枢神経系疾患の治験におけるエンドポイント:広く採用されている複数のエンドポイントと評価スケール Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted
出版日: 2011年11月22日 ページ情報: 英文 216 Pages
概要

当レポートでは、中枢神経系疾患の治験におけるエンドポイント(評価項目)について調査分析し、安全性と有効性に重点を置いた中枢神経系疾患の市販薬について検証し、製品プロファイリング、疾患別の製品パイプライン評価などを提供し、主要企業のプロファイルも含めて、概略以下の構成でお届けいたします。

第1章 目次

第2章 中枢神経系疾患における治験デザイン:概要

  • イントロダクション
  • 治験結果の種類
    • 一次結果
    • 二次結果
  • ガイダンス

第3章 主要な中枢神経系疾患と製品プロファイリング

  • 主要な中枢神経系疾患の市販薬のエンドポイントと規制認可
    • アルツハイマー病
    • 鬱病
    • てんかん
    • パーキンソン病
    • 統合失調症

第4章 中枢神経系疾患の市販薬と製品パイプライン評価

  • アルツハイマー病
    • 一次エンドポイント
    • 二次エンドポイント
    • 主な市販薬:安全性と有効性の分析
    • 第III相試験の分析
    • 最も有望な薬剤のプロファイル
    • 第II相試験の分析
    • 終了した治験の分析
  • 鬱病
    • 一次エンドポイント
    • 二次エンドポイント
    • 主な市販薬:安全性と有効性の分析
    • 第III相試験の分析
    • 最も有望な薬剤のプロファイル
    • 第II相試験の分析
    • 終了した治験の分析
  • てんかん
    • 一次エンドポイント
    • 二次エンドポイント
    • 主な市販薬:安全性と有効性の分析
    • 第III相試験の分析
    • 最も有望な薬剤のプロファイル
    • 第II相試験の分析
    • 終了した治験の分析
  • パーキンソン病
    • 一次エンドポイント
    • 二次エンドポイント
    • 主な市販薬:安全性と有効性の分析
    • 第III相試験の分析
    • 最も有望な薬剤のプロファイル
    • 第II相試験の分析
    • 終了した治験の分析
  • 統合失調症
    • 一次エンドポイント
    • 二次エンドポイント
    • 主な市販薬:安全性と有効性の分析
    • 第III相試験の分析
    • 最も有望な薬剤のプロファイル
    • 第II相試験の分析
    • 終了した治験の分析

第5章 企業プロファイル

  • Pfizer Inc.
  • Glaxo Smith Kline Plc
  • Astra Zeneca Plc
  • Sanofi
  • Johnson & Johnson
  • Eli Lilly and Company
  • Novartis AG
  • Abbott Laboratories
  • Forest Laboratories, Inc
  • エーザイ

第6章 付録

図表

目次

Summary

GBI Research, the leading business intelligence provider, has released its latest research “Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted” which provides an insight into different endpoints that are used for the central nervous system (CNS) in clinical trials. The report examines different aspects under clinical trial endpoints in central nervous system disorders such as analysis on major marketed central nervous system drugs with an emphasis on safety and efficacy details. Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, most promising central nervous system drugs with details on safety, efficacy and clinical trials, and terminated trial analysis. The company profiling highlights the central nervous system drugs of different companies.

The global CNS disease market is valued as $53.1 billion in 2010 that grew from $36.8 billion in 2002 with a CAGR of 4.7%. An increased geriatric population in many countries combined with increased life expectancy is expected to increase disease population of CNS disease. The product pipeline of CNS disease is promising with many novel molecules with disease modifying characteristics at various stages of development and is expected to fulfill the unmet needs in the CNS disease market. The product pipeline for multiple sclerosis has many orally administered novel molecules whereas for alzheimer's disease, the product pipeline have novel molecules such as Bapineuzumab, Solanezumab, BMS-708163 that target the underlying causes of the disease and thus may offer significant benefits to the patients. The market for Schizophrenia and bipolar disorder is estimated to be driven by the anticipated launch of AZ-004 and other molecules such as Cariprazine, Zicronapine, RG1678 and Aripiprazole Depot injection. The continued uptake of non stimulants and expected launch of Kapvay and other pipeline molecules will have significant impact on market for ADHD. Although in upcoming years the market will witness patent expiries of major drugs, however this will be offset by the rapid uptake of new molecules, which will stabilize the market decline. The market is expected to grow with a CAGR of 1.4% from 2010 to 2017 to reach $58.6 billion in 2017.

This report details "Endpoints - Clinical Trials in Central nervous system Disorders", highlighting the five major central nervous system disorders which are Alzheimer's disease, Depression, Epilepsy, Parkinson's disease and Schizophrenia. The classification of five major central nervous system diseases is done on the basis of, the number of pipeline molecules present in Phase III stage of development.

The term endpoint refers to an outcome or measure of a clinical trial. Endpoints can include all kinds of aspects, those related to the effectiveness of treatment and others. However, the endpoint selection must take into account the need to obtain the highest information of therapeutic interest with the least risk and discomfort for the individual. Also, the endpoints must be to the objective of the study and represent the most effective way to assess pharmacological response.

Scope

  • Data and analysis on the marketed products and analysis of their efficacy and safety details
  • Analysis of the five major Central nervous system diseases which include Alzheimer's disease, depression, epilepsy, Parkinson's disease and schizophrenia
  • Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Also analysis of terminated trials is included in this chapter. Only industry sponsored studies are included in the report.
  • Analysis on most promising molecules of five major central nervous system diseases with emphasis on their efficacy and safety details.
  • Company Profiling talks in detail about the companies, which are strong in the market.

Reasons to buy

  • Understand the trends in clinical trial endpoints used for central nervous system diseases
  • Build effective strategies to launch their pipeline products by identifying the right endpoints
  • Understanding and applying Surrogate endpoints and Clinical Biomarkers as endpoints for central nervous system diseases
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.

Executive Summary

GBI Research, the leading business intelligence provider, has released its latest research “Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted” which provides an insight into different endpoints used for the central nervous system in clinical trials. The report examines different aspects under clinical trial endpoints in central nervous system disorders such as analysis on major marketed Central nervous system drugs with an emphasis on safety and efficacy details, Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, most promising Central nervous system drugs with details on safety, efficacy and clinical trials, and terminated trial analysis. The company profiling highlights the central nervous system drugs of different companies.

The global CNS disease market is valued as $53.1 billion in 2010 that grew from $36.8 billion in 2002 with a CAGR of 4.7%. An increase in geriatric population in many countries combined with increased life expectancy is expected to increase disease population of CNS disease. The product pipeline of CNS disease is promising with many novel molecules with disease modifying characteristics at various stages of development, which are expected to fulfill the unmet needs in the CNS disease market. The product pipeline for the multiple sclerosis has many orally administered novel molecules whereas for alzheimer's disease, the product pipeline have novel molecules such as Bapineuzumab, Solanezumab, BMS-708163 which target the underlying causes of the disease and thus may offer significant benefits to the patients. The market for Schizophrenia and bipolar disorder is estimated to be driven by the anticipated launch of AZ-004 and other molecules such as Cariprazine, Zicronapine, RG1678 and Aripiprazole Depot injection. The continued uptake of non stimulants and expected launch of Kapvay and other pipeline molecules will have significant impact on market for ADHD. Although in upcoming years market will witness the patent expiries of major drugs, however rapid uptake of new molecules will stabilize the market decline and the market is expected to grow with a CAGR of 1.4% from 2010 to 2017 to reach $58.6 billion in 2017.

This report details “Endpoints - Clinical Trials in Central nervous system Disorders”, highlighting the five major central nervous system disorders which are Alzheimer's disease, Depression, Epilepsy, Parkinson's disease and Schizophrenia. The classification of five major central nervous system diseases is done on the basis of, the number of pipeline molecules present in Phase III stage of development.

The term endpoint refers to an outcome or measure of a clinical trial. Endpoints can include all kinds of aspects, those related to the effectiveness of treatment and others. However, the endpoint selection must take into account the need to obtain the highest information of therapeutic interest with the least risk and discomfort for the individual. Also, the endpoints must be to the objective of the study and represent the most effective way to assess pharmacological response.

Rating Scales Are Important Tools in the Evaluation of Clinical Trials for Central Nervous System Disorders

The effectiveness of new drugs against disorders affecting the central nervous system is greatly dependent on the use of rating scales in randomized clinical trials. Some of the ratings scales used in clinical trials for drugs targeting CNS disorders include the Brief Psychiatric Rating Scale (BPRS), Positive and Negative Syndrome Scale (PANSS), the Hamilton Depression and Anxiety Scales (HAM-D and HAM-A), the Mini-Mental State Examination (MMSE). These scales have been widely used in disorders such as Depression, Epilepsy, Alzheimers and Schizophrenia. Although these measures are subjective, their use stems from the fact that they provide a sufficiently high degree of reliability and validity on trait performance.

Multiple Endpoints are Used as a Measure While Evaluating Clinical Trials for Central Nervous System Disorders

Use of multiple endpoints is shown in five indications studied in the central nervous system disorder segment. This is because most clinical states are inter-dependent and hence it becomes important to study more than one or two endpoints. Except for depression, which has only bout 33% of the trials measured with multiple endpoints, the other four indications have more than 40% of trials measured by multiple endpoints.

Safety and Efficacy Issues, Failure to Meet Primary and Secondary Endpoints Led to Discontinuation of Most of the Drugs

In November 2005, Neurocrine Biosciences had initiated a Phase III, multi-center, randomized, double-blind, placebo-controlled study of the efficacy and tolerability of Indiplon therapy initiated with Sertraline versus Sertraline monotherapy in subjects with insomnia and co-existing major depressive disorder. The goal of this study was to determine whether Indiplon, when administered with Sertraline, improves insomnia symptoms and depressive symptoms in subjects with both insomnia and depression. The primary outcome measure was to evaluate the change in subjective total sleep time (sTST), from baseline to average of the week one data. The secondary outcome measure was to evaluate the change from baseline in subjective total sleep time (sTST). Change from baseline in subjective parameters were to be determined according to the latency to sleep onset (sLSO), number of awakenings after sleep onset (sNAASO), wake time after sleep onset (sWASO), Sleep Quality (IVR) criteria and to asses the change from baseline in the 3-item HAM-D insomnia factor was also to be assessed. The further development of the combination therapy was terminated.

Cephalon, Inc was engaged in the development of CEP-1347. CEP-1347 was under development for the treatment of Asthma, Parkinson's and Alzheimer's diseases. The drug candidate was in Phase III stage of development. In May 2005 Cephalon, Inc. and H. Lundbeck A/S announced the discontinuation of their Phase II/III clinical trial of CEP-1347 in Parkinson's disease. An independent data monitoring committee just completed a planned review of interim results and concluded that the data are unlikely to provide evidence of significant effect.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Clinical Trial Design in Central Nervous System - Overview

  • 2.1. Introduction
  • 2.2. Types of Clinical Trial Outcomes
    • 2.2.1. Primary Outcomes
    • 2.2.2. Secondary Outcomes
  • 2.3. GBI Research Report Guidance

3. Endpoints - Clinical Trials in CNS Disorders - Top Five CNS Disorders and their Product Profiling

  • 3.1. Endpoints-Major Marketed Drugs of Top Five Central Nervous System Disorders and their Regulatory Approval
    • 3.1.1. Alzheimer's disease
    • 3.1.2. Depression
    • 3.1.3. Epilepsy
    • 3.1.4. Parkinson's disease
    • 3.1.5. Schizophrenia

4. Endpoints - Clinical Trials in CNS Disorders -Marketed and Pipeline Product Assessments

  • 4.1. Alzheimer's disease
    • 4.1.1. Primary Endpoints used in Alzheimer's disease Clinical Trials
    • 4.1.2. Secondary Endpoints used in Alzheimer's disease Clinical Trials
    • 4.1.3. Major Marketed Drugs-Safety and Efficacy Analysis
    • 4.1.4. Phase III Clinical Trial Analysis
    • 4.1.5. Most Promising Drugs' Profiles
    • 4.1.6. Phase II Clinical Trial Analysis
    • 4.1.7. Terminated Trials Analysis
  • 4.2. Depression
    • 4.2.1. Primary Endpoints used in Clinical Trials for Depression
    • 4.2.2. Secondary Endpoints used in Clinical Trials for Depression
    • 4.2.3. Major Marketed Drugs-Safety and Efficacy Analysis
    • 4.2.4. Phase III Clinical Trial Analysis
    • 4.2.5. Most Promising Drugs' Profiles
    • 4.2.6. Phase II Clinical Trial Analysis
    • 4.2.7. Terminated Trials Analysis
  • 4.3. Epilepsy
    • 4.3.1. Primary Endpoints used in Clinical Trials for Epilepsy
    • 4.3.2. Secondary Endpoints used in Clinical Trials for Epilepsy
    • 4.3.3. Major Marketed Drugs-Safety and Efficacy Analysis
    • 4.3.4. Phase III Clinical Trial Analysis
    • 4.3.5. Most Promising Drugs' Profiles
    • 4.3.6. Phase II Clinical Trial Analysis
    • 4.3.7. Terminated Trials Analysis
  • 4.4. Parkinson's disease
    • 4.4.1. Primary Endpoints used in Clinical Trials for Parkinson's disease
    • 4.4.2. Secondary Endpoints used in Clinical Trials Parkinson's disease
    • 4.4.3. Major Marketed Drugs-Safety and Efficacy Analysis
    • 4.4.4. Phase III Clinical Trial Analysis
    • 4.4.5. Most Promising Drugs' Profiles
    • 4.4.6. Phase II Clinical Trial Analysis
    • 4.4.7. Terminated Trials Analysis
  • 4.5. Schizophrenia
    • 4.5.1. Primary Endpoints used in Clinical Trials for Schizophrenia
    • 4.5.2. Secondary Endpoints used in Clinical Trials for Schizophrenia
    • 4.5.3. Major Marketed Drugs-Safety and Efficacy Analysis
    • 4.5.4. Phase III Clinical Trial Analysis
    • 4.5.5. Most Promising Drugs' Profiles
    • 4.5.6. Phase II Clinical Trial Analysis
    • 4.5.7. Terminated Trials Analysis

5. Endpoints - Clinical Trials in CNS Disorders - Company Profiles

  • 5.1. Pfizer Inc.
    • 5.1.1. Company Profile
    • 5.1.2. Major Central Nervous System Disorders Products
  • 5.2. GlaxoSmithKline Plc
    • 5.2.1. Company Profile
    • 5.2.2. Major Central Nervous System Disorders Products
  • 5.3. AstraZeneca Plc
    • 5.3.1. Company Profile
    • 5.3.2. Major Central Nervous System Disorders Products
  • 5.4. Sanofi
    • 5.4.1. Company Profile
    • 5.4.2. Major Central Nervous System Disorders Products
  • 5.5. Johnson & Johnson
    • 5.5.1. Company Profile
    • 5.5.2. Major Central Nervous System Disorders Products
  • 5.6. Eli Lilly and Company
    • 5.6.1. Company Profile
    • 5.6.2. Major Central Nervous System Disorders Products
  • 5.7. Novartis AG
    • 5.7.1. Company Profile
    • 5.7.2. Major Central Nervous System Disorders Products
  • 5.8. Abbott Laboratories
    • 5.8.1. Company Profile
    • 5.8.2. Major Central Nervous System Disorders Products
  • 5.9. Forest Laboratories, Inc
    • 5.9.1. Company Profile
    • 5.9.2. Major Central Nervous System Disorders Products
  • 5.10. Eisai Co., Ltd.
    • 5.10.1. Company Profile
    • 5.10.2. Major Central Nervous System Disorders Products

6. Endpoints - Clinical Trials in CNS Disorders - Appendix

  • 6.1. Market Definitions
  • 6.2. Abbreviations
  • 6.3. Research Methodology
    • 6.3.1. Clinical Trial Design Overview
    • 6.3.2. Marketed and Pipeline Products Assessment
    • 6.3.3. Company Profiles
  • 6.4. Contact Us
  • 6.5. Disclaimer
  • 6.6. Sources

List of Tables

  • Table 1: Endpoints - Clinical Trials in CNS Disorders, Alzheimer's disease, Endpoints for Major Marketed Drugs, Global,1990- 2010
  • Table 2: Endpoints - Clinical Trials in CNS Disorders, Depression, Endpoints for Major Marketed Drugs, Global,1990- 2010
  • Table 3: Endpoints - Clinical Trials in CNS Disorders, Epilepsy, Endpoints for Major Marketed Drugs, Global,1990- 2010
  • Table 4: Endpoints - Clinical Trials in CNS Disorders, Parkinson's disease, Endpoints for Major Marketed Drugs, Global, 1990- 2010
  • Table 5: Endpoints - Clinical Trials in CNS Disorders, Parkinson's disease, Endpoints for Major Marketed Drugs, Global, 1990- 2010
  • Table 6: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Completed Phase III Trial Molecules, Secondary Endpoints, Global, 2000-2010
  • Table 7: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Ongoing Phase III Trial Molecules, Secondary Endpoints, Global, 2000-2010
  • Table 8: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Completed Phase II Trial Molecules, Secondary Endpoints, Global, 2000-2010
  • Table 9: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Ongoing Phase II Trial Molecules, Secondary Endpoints, Global, 2000-2010
  • Table 10: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Alzheimer's Disease
  • Table 11: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Trial Molecules, Primary Endpoints, Global, 2000-2010
  • Table 12: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Ongoing Phase III Trial Molecules, Primary Endpoints, Global, 2000-2010
  • Table 13: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Ongoing Phase III Trial Molecules, Secondary Endpoints, Global, 2000-2010
  • Table 14: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Trial Molecules, Primary Endpoints, Global, 2000-2010
  • Table 15: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Ongoing Phase II Trial Molecules, Primary Endpoints, Global, 2000-2010
  • Table 16: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Ongoing Phase II Trial Molecules, Secondary Endpoints, Global, 2000-2010
  • Table 17: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Depression
  • Table 18: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
  • Table 19: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
  • Table 20: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
  • Table 21: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase II Trial Molecules, Primary Endpoints, Global, 2000-2010
  • Table 22: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase II Trial Molecules, Secondary Endpoints, Global, 2000-2010
  • Table 23: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Epilepsy
  • Table 24: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Completed Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
  • Table 25: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Ongoing Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
  • Table 26: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Completed Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
  • Table 27: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Ongoing Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
  • Table 28: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Parkinson's Disease
  • Table 29: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
  • Table 30: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
  • Table 31: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
  • Table 32: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010
  • Table 33: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Schizophrenia
  • Table 34: Endpoints- Clinical Trials in Central Nervous Disorders, Pfizer Inc, Major Central Nervous Drugs, 2010
  • Table 35: Endpoints- Clinical Trials in Central Nervous Disorders, GlaxoSmithKline Plc, Major Central Nervous Drugs, 2010
  • Table 36: Endpoints- Clinical Trials in Central Nervous Disorders, AstraZeneca Plc, Major Central Nervous Drugs, 2010
  • Table 37: Endpoints- Clinical Trials in Central Nervous Disorders, Sanofi, Major Central Nervous Drugs, 2010
  • Table 38: Endpoints- Clinical Trials in Central Nervous Disorders, Johnson & Johnson, Major Central Nervous Drugs, 2010
  • Table 39: Endpoints- Clinical Trials in Central Nervous Disorders, Eli Lilly & Company, Major Central Nervous Drugs, 2010
  • Table 40: Endpoints- Clinical Trials in Central Nervous Disorders, Novartis AG, Major Central Nervous Drugs, 2010
  • Table 41: Endpoints- Clinical Trials in Central Nervous Disorders, Abbott Laboratories, Major Central Nervous Drugs, 2010
  • Table 42: Endpoints- Clinical Trials in Central Nervous Disorders, Forest Laboratories, Inc., Major Central Nervous Drugs, 2010
  • Table 43: Endpoints- Clinical Trials in Central Nervous Disorders, Eisai Co., Inc., Major Central Nervous Drugs, 2010

List of Figures

  • Figure 1: Endpoints - Clinical Trials in CNS Disorders, Number of Pipeline products in Phase III Stage of Development, 2011
  • Figure 2: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 3: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
  • Figure 4: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Completed Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
  • Figure 5: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 6: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Completed Phase III Clinical Trials Classified Based on Rare Secondary Endpoints, Global, 2000-2010
  • Figure 7: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 8: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Completed Phase III Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 9: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 10: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Ongoing Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
  • Figure 11: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 12: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Ongoing Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 13: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Ongoing Phase III Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 14: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 15: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
  • Figure 16: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Completed Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
  • Figure 17: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 18: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Completed Phase II Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010
  • Figure 19: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Completed Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 20: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Completed Phase II Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 21: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 22: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Ongoing Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
  • Figure 23: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Ongoing Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 24: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Ongoing Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 25: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimer's Disease, Ongoing Phase II Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 26: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 27: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
  • Figure 28: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
  • Figure 29: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 30: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010
  • Figure 31: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 32: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 33: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
  • Figure 34: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
  • Figure 35: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 36: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 37: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 38: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
  • Figure 39: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 40: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010
  • Figure 41: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 42: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 43: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 44: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 45: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 46: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
  • Figure 47: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 48: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010
  • Figure 49: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 50: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 51: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 52: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
  • Figure 53: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Completed Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
  • Figure 54: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 55: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 56: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Completed Phase III Clinical Trials Classified Based on Rare Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 57: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 58: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 59: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Ongoing Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 60: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 61: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
  • Figure 62: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Completed Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
  • Figure 63: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 64: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Completed Phase II Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010
  • Figure 65: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Completed Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 66: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Completed Phase II Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 67: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 68: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Ongoing Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
  • Figure 69: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Ongoing Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 70: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinson's Disease, Ongoing Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 71: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 72: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
  • Figure 73: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
  • Figure 74: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Other Multiple Primary Endpoints, Global, 2000-2010
  • Figure 75: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 76: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010
  • Figure 77: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 78: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 79: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 80: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 81: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010
  • Figure 82: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 83: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010
  • Figure 84: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010
  • Figure 85: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
  • Figure 86: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010
  • Figure 87: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010
Back to Top